# K2 Oncology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/k2-oncology

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Website: www.k2oncology.cn
- Latest round: Series B (Aug 4, 2022)
- Investors on record: 5

## About

Founded in 2016 and based in Beijing, China, K2 Oncology is a a medical technology that focuses on the development of anti-tumor drugs. The company has an R&D center of 800 square meters, a clinical medical laboratory of 1300 square meters and a GMP-level cell culture production workshop. Zhijian Sun, founder and CEO of the company, was a senior researcher at BeiGene and the head of in vitro pharmacology of the innovative drug zanubrutinib.

The company has iaCyte organoid technology platform, human cell stem cell culture technology platform PDOX technology platform and organoid culture medium kit, etc. OrganoProTM Organoid Medium Kit is suitable for organoid culture of gastric cancer, ovarian cancer and breast cancer.

## Funding rounds

- Series B, Aug 4, 2022 — FOF Capital
- Series A, Aug 27, 2018 — Detong Capital, Tongsheng Equity Investment, Qihang Capital
- Angel, Nov 1, 2016 — Tengye Ventures

## Investors

- Tengye Ventures (https://capitalatlas.ai/funds/tengye-ventures) — Angel
- Detong Capital (https://capitalatlas.ai/funds/detong-capital) — Series A
- Tongsheng Equity Investment (https://capitalatlas.ai/funds/tongsheng-equity-investment) — Series A
- Qihang Capital (https://capitalatlas.ai/funds/qihang-capital) — Series A
- FOF Capital (https://capitalatlas.ai/funds/fof-capital) — Series B